JPH11511257A - アルツハイマー病を診断およびモニターするためのp97の定量 - Google Patents
アルツハイマー病を診断およびモニターするためのp97の定量Info
- Publication number
- JPH11511257A JPH11511257A JP9509656A JP50965697A JPH11511257A JP H11511257 A JPH11511257 A JP H11511257A JP 9509656 A JP9509656 A JP 9509656A JP 50965697 A JP50965697 A JP 50965697A JP H11511257 A JPH11511257 A JP H11511257A
- Authority
- JP
- Japan
- Prior art keywords
- amount
- disease
- test sample
- alzheimer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.患者からの体液試料中のp97を定量することによってアルツハイマー病 を診断する方法であって、以下の工程: (a)アルツハイマー病に罹患していることが疑われる患者から体液試料を採取 することにより試験試料を得; (b)試験試料中のp97の量を測定し;そして (c)試験試料中のp97の量を、対照試料中のp97の量と比較する; からなり、 対照試料中のp97の量と比較して増加している試験試料中のp97の量の存在 をアルツハイマー病の可能性の指標とする方法。 2.試験試料中のp97の量が対照試料中のp97の量と比較して1.5倍ま たはそれ以上に増加していることを、アルツハイマー病の可能性の指標とする請 求項1に記載の方法。 3.試験試料中のp97の量が対照試料中のp97の量と比較して2〜9倍に 増加していることを、アルツハイマー病の可能性の指標とする請求項1に記載の 方法。 4.工程(c)において、試験試料中のp97の量を、対照試料において測定し たp97の平均またはベースライン量と比較する請求項1に記載の方法。 5.(c)における対照試料が、同一の患者または別の個体からの正常試料であ る請求項1に記載の方法。 6.アルツハイマー病に罹患している患者からの体液試料中のp97を定量す ることによってアルツハイマー病の進行をモニターする方法であって、以下の工 程: (a)患者から体液試料を採取することにより試験試料を得; (b)試験試料中のp97の量を測定し;そして (c)試験試料中のp97の量を、先に個体から採取した第1の試験試料中のp 97の量と比較する; からなり、 第1の試験試料中のp97の量と比較して増加している試験試料中のp97の量 の存在を、個体のアルツハイマー病の進行の指標とする方法。 7.アルツハイマー病に罹患している患者からの体液試料中のp97を定量す ることによってアルツハイマー病の治療をモニターする方法であって、以下の工 程: (a)治療を受けている患者から体液試料を採取することにより試験試料を得; (b)試験試料中のp97の量を測定し;そして (c)試験試料中のp97の量を、治療前に患者から採取した治療前試料中のp 97の量と比較する; からなり、 治療前試料中のp97の量と比較したときの試験試料中のp97の量の差異を、 治療効果の指標とする方法。 8.体液が血清またはCSFである請求項1〜7のいずれかに記載の方法。 9.工程(b)におけるp97の量がp97に対する抗体を用いて測定される請 求項1〜7のいずれかに記載の方法。 10.試験試料中のp97の存在を検出する反応物質およびp97の存在を検 出するための試薬を含む、請求項1、6または7のいずれかに記載の方法を実施 するためのキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US520,933 | 1990-05-09 | ||
US08/520,933 US5981194A (en) | 1992-07-10 | 1995-08-31 | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
US08/520,933 | 1995-08-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11511257A true JPH11511257A (ja) | 1999-09-28 |
JP3259963B2 JP3259963B2 (ja) | 2002-02-25 |
Family
ID=24074638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50965697A Expired - Lifetime JP3259963B2 (ja) | 1995-08-31 | 1996-08-30 | アルツハイマー病を診断およびモニターするためのp97の定量 |
Country Status (11)
Country | Link |
---|---|
US (3) | US5981194A (ja) |
EP (1) | EP0847530B1 (ja) |
JP (1) | JP3259963B2 (ja) |
CN (1) | CN1198214A (ja) |
AT (1) | ATE269545T1 (ja) |
AU (1) | AU717198B2 (ja) |
CA (1) | CA2230372C (ja) |
DE (1) | DE69632734T2 (ja) |
IL (1) | IL123441A (ja) |
NZ (1) | NZ315997A (ja) |
WO (1) | WO1997008560A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003525038A (ja) * | 2000-02-08 | 2003-08-26 | ユニバーシティー オブ ブリティッシュ コロンビア | 治療薬をスクリーニングするための組成物および方法 |
JP2011516419A (ja) * | 2008-03-28 | 2011-05-26 | カイナ エルエルシー | 鉄欠乏性障害を治療するためのフェリチンの使用 |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905817B1 (en) * | 1998-10-01 | 2005-06-14 | Licestia Ltd. | Ret-independent signaling pathway for GDNF |
JP4414023B2 (ja) * | 1999-08-05 | 2010-02-10 | オリエンタル酵母工業株式会社 | 関節炎関連メラノトランスフェリンの測定方法および試薬 |
US6586239B1 (en) * | 2000-01-07 | 2003-07-01 | Agy Therapeutics, Inc. | Purifying microglial cells by binding cell Fc receptor to immunoglobulin G Fc domain |
US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
PT1346041E (pt) * | 2000-11-27 | 2007-06-05 | Praecis Pharm Inc | Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica. |
US7629309B2 (en) * | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
ES2300439T3 (es) * | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20040005309A1 (en) * | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
DE60234057D1 (de) * | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
US8129504B2 (en) * | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US20030072761A1 (en) * | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
AU2003222568B2 (en) * | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
US7636597B2 (en) | 2002-11-14 | 2009-12-22 | Brainsgate, Ltd. | Surgical tools and techniques for stimulation |
US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
CA2491661A1 (en) * | 2002-07-12 | 2004-01-22 | Biomarin Pharmaceutical Inc. | The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
AU2003286553A1 (en) * | 2002-10-18 | 2004-05-04 | Promega Corporation | Methods for separating molecules |
EP1626735B1 (en) * | 2003-05-09 | 2014-11-19 | Transfert Plus | Compound for treating cancer caused by cells expressing melanotransferrin at their surface |
US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
DE602005020745D1 (de) * | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
DE602005020755D1 (de) * | 2004-03-05 | 2010-06-02 | Univ Illinois | Peptidträger für die verabreichung von arzneimitteln |
EP2099523A2 (en) * | 2006-11-13 | 2009-09-16 | ZyStor Therapeutics , Inc. | Methods for treating pompe disease |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
ES2830350T3 (es) | 2008-05-07 | 2021-06-03 | Biomarin Pharm Inc | Péptidos de dirección lisosómica y usos de los mismos |
ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
PL2717917T3 (pl) | 2011-07-05 | 2016-12-30 | Koniugaty p97 - przeciwciało | |
DK2739649T3 (en) | 2011-08-05 | 2018-01-08 | Bioasis Technologies Inc | P97 FRAGMENTS WITH TRANSFER ACTIVITY |
JP6433424B2 (ja) | 2012-07-31 | 2018-12-05 | バイオアシス テクノロジーズ インコーポレイテッド | 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法 |
BR112015022416A2 (pt) | 2013-03-13 | 2017-10-24 | Bioasis Technologies Inc | fragmentos de p97 e seus usos |
EP2878335B1 (en) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US20160347821A1 (en) | 2014-02-03 | 2016-12-01 | Bioasis Technologies, Inc. | P97 fusion proteins |
ES2762672T3 (es) | 2014-02-19 | 2020-05-25 | Bioasis Technologies Inc | Proteínas de fusión de P97-IDS |
JP6847664B2 (ja) | 2014-05-01 | 2021-03-24 | バイオアシス テクノロジーズ インコーポレイテッド | P97−ポリヌクレオチド複合体 |
TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
EP3093043B1 (en) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US11752315B1 (en) | 2016-10-07 | 2023-09-12 | Carlos A. Hakim | Method of treating normal pressure hydrocephalus |
US10473672B2 (en) * | 2017-02-09 | 2019-11-12 | Kaohsiung Chang Gung Memorial Hospital | Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers |
CN113430146B (zh) * | 2021-07-28 | 2023-03-17 | 西安医学院 | 表达石杉碱甲的苏云金芽孢杆菌hw1株及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
GB2116979B (en) * | 1982-02-25 | 1985-05-15 | Ward Page Faulk | Conjugates of proteins with anti-tumour agents |
US4522750A (en) * | 1984-02-21 | 1985-06-11 | Eli Lilly And Company | Cytotoxic compositions of transferrin coupled to vinca alkaloids |
GB2188637B (en) * | 1986-02-07 | 1990-11-14 | Oncogen | Vaccines against melanoma |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5034223A (en) * | 1986-10-09 | 1991-07-23 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5527527A (en) | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5182107A (en) | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
DE69331100T2 (de) * | 1992-07-10 | 2002-08-14 | Univ British Columbia | Verwendung von p97 in der diagnose von morbus alzheimer |
-
1995
- 1995-08-31 US US08/520,933 patent/US5981194A/en not_active Expired - Lifetime
-
1996
- 1996-08-30 DE DE69632734T patent/DE69632734T2/de not_active Expired - Lifetime
- 1996-08-30 WO PCT/CA1996/000587 patent/WO1997008560A1/en active IP Right Grant
- 1996-08-30 AT AT96928295T patent/ATE269545T1/de not_active IP Right Cessation
- 1996-08-30 NZ NZ315997A patent/NZ315997A/xx not_active IP Right Cessation
- 1996-08-30 EP EP96928295A patent/EP0847530B1/en not_active Expired - Lifetime
- 1996-08-30 CN CN96197251A patent/CN1198214A/zh active Pending
- 1996-08-30 AU AU67834/96A patent/AU717198B2/en not_active Expired
- 1996-08-30 IL IL12344196A patent/IL123441A/xx not_active IP Right Cessation
- 1996-08-30 JP JP50965697A patent/JP3259963B2/ja not_active Expired - Lifetime
- 1996-08-30 CA CA002230372A patent/CA2230372C/en not_active Expired - Lifetime
-
1999
- 1999-04-01 US US09/285,040 patent/US6455494B1/en not_active Expired - Fee Related
-
2002
- 2002-04-29 US US10/133,642 patent/US20030077693A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003525038A (ja) * | 2000-02-08 | 2003-08-26 | ユニバーシティー オブ ブリティッシュ コロンビア | 治療薬をスクリーニングするための組成物および方法 |
JP2011516419A (ja) * | 2008-03-28 | 2011-05-26 | カイナ エルエルシー | 鉄欠乏性障害を治療するためのフェリチンの使用 |
Also Published As
Publication number | Publication date |
---|---|
NZ315997A (en) | 1999-08-30 |
EP0847530A1 (en) | 1998-06-17 |
ATE269545T1 (de) | 2004-07-15 |
CA2230372C (en) | 2008-04-29 |
IL123441A0 (en) | 1998-09-24 |
DE69632734T2 (de) | 2005-06-30 |
IL123441A (en) | 2001-01-11 |
AU6783496A (en) | 1997-03-19 |
EP0847530B1 (en) | 2004-06-16 |
US6455494B1 (en) | 2002-09-24 |
WO1997008560A1 (en) | 1997-03-06 |
CN1198214A (zh) | 1998-11-04 |
US20030077693A1 (en) | 2003-04-24 |
JP3259963B2 (ja) | 2002-02-25 |
CA2230372A1 (en) | 1997-03-06 |
US5981194A (en) | 1999-11-09 |
AU717198B2 (en) | 2000-03-23 |
DE69632734D1 (de) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3259963B2 (ja) | アルツハイマー病を診断およびモニターするためのp97の定量 | |
Kennard et al. | Serum levels of the iron binding protein p97 are elevated in Alzheimer′ s disease | |
US5270165A (en) | Method of diagnosis of amyloidoses | |
US6495335B2 (en) | Compositions and methods for diagnosing alzheimer's disease | |
US6680173B2 (en) | Diagnosis of tauopathies | |
JP2007517188A (ja) | 発作性脳発射を評価するための免疫吸着血液検査 | |
JP2008528974A (ja) | 虚血バイオマーカー及び手術による神経学的有害事象を予測するためのその使用 | |
US8298784B2 (en) | In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases | |
JP2002524740A (ja) | 初期cnsダメージのマーカーとしてのタウ | |
WO2008031190A1 (en) | Alpha-1-antitrypsin as a diagnostic/prognostic indicator for neurodegenerative diseases | |
EP2653872B1 (en) | Biomarker for amyloid-beta -related neurological disorders | |
CA2473866A1 (en) | Diagnosis of dementia utilizing thrombospondin | |
JP2009513960A (ja) | 神経変性疾患を診断するためのinvitro方法 | |
US9618522B2 (en) | Diagnostic testing in dementia and methods related thereto | |
MXPA98001641A (en) | Quantification of p97 to diagnose and monitor alzhei's disease | |
US20230273220A1 (en) | Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection | |
US20220308073A1 (en) | Biomarker for alzheimer's disease | |
KR101250464B1 (ko) | 혈장 내 pgcp 농도 측정을 통한 치매 진단 방법 | |
US20220050118A1 (en) | Method for diagnosing a liver disease | |
KR20230148764A (ko) | 알츠하이머병 또는 경도 인지장애 진단을 위한 비응집성 용해조성물 및 이를 이용한 진단 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071214 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081214 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081214 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091214 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091214 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101214 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101214 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111214 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121214 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121214 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131214 Year of fee payment: 12 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |